

Target	
Mechanism of Action	<ul style="list-style-type: none"> NF-kB signaling suppression through MALT1 inhibition
Indication - Primary	<ul style="list-style-type: none"> Hematological cancers (Malt Lymphoma, ABC DLBCL)
Indication - Expansion	<ul style="list-style-type: none"> -
Route of Administration	<ul style="list-style-type: none"> IP
Competitive Advantage	<ul style="list-style-type: none"> Opportunity for First-in-class drug discovery program Clear patient stratification possibility
Data Files	<ul style="list-style-type: none"> In vitro: <ul style="list-style-type: none"> Malt1 biochemical assay Cancer cell cytotoxicity
IP Status	<ul style="list-style-type: none"> Under preparation
Collaboration Model	<ul style="list-style-type: none"> Collaborative research followed by licensing out
Contact (Science)	<ul style="list-style-type: none"> Sang-Un Choi (suchoi@kRICT.re.kr, +82-42-860-7545) Chi Hoon Park (, chpark@kRICT.re.kr, +82-42-860-7161)
Contact (Licensing)	<ul style="list-style-type: none"> Moon Geun Jung (Technology marketing office, mgjung@kRICT.re.kr, +82-42-860-7746) Choon-gil Kim (Technology marketing office, joykim@kRICT.re.kr, +82-42-860-7079) Kyung Sun Choi (Technology marketing office, chanian@kRICT.re.kr, +82-42-860-7076)